PROTEIN O-GLYCOSYLATION IN CRYPTOCOCCUS NEOFORMANS

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 为支持NCRR生物医学血糖基金的目标而开发的技术适用于许多不同的系统。用于表征多聚糖的无偏方法具有足够的灵敏度，可以检测到较小的多聚糖。Doering实验室之前已经产生了隐球菌突变体，这些突变体由于多糖合成的改变而呈现出改变的胶囊形态。这些突变基因的糖链产物并不总是为人所知。我们已经使用我们的糖学技术鉴定了XYL和Man之间的一种新的磷酸二酯连接，它是一种特定的木磷酸转移酶的产物。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Technology developed in support of the aims of the NCRR Biomedical Glycomics grant is applicable to many different systems. The non-biased methods for glycan characterization are sufficiently sensitive to allow detection of minor glycans. The Doering lab has previously generated Cryptococcus mutants that present altered capsule morphology as a result of altered glycan synthesis. The glycan products of these mutant genes are not always known. We have used our glycomic technology to identify a novel phosphodiester linkage between Xyl and Man as a product of a specific xylosylphosphotransferase.